Autism
Conditions
Interventions
Intervention group of autistic children:Yuze Skin Barrier Recovery Body Lotion (G2023005141, specification: 280ml/ piece) will be applied on the whole body twice a day (once in the morning and once in
Control group of autistic children:None
Control group of healthy children:None
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: Healthy children: Healthy children aged 3-12 years with no mental illness and no skin lesions on both forearms. Autistic children: (1) Children with autism spectrum disorder diagnosed by a child psychiatrist or developmental pediatrician, child psychotherapist, or child rehabilitator and who meet the DSM-5 diagnostic criteria. (2) Diagnostic verification was performed according to CARS-2. (3) Children aged 3-12 years. (4) There have been no major changes in behavior or medical treatment in the past two months and no changes are intended for the next two months of the study.
Exclusion criteria
Exclusion criteria: Healthy children: (1) Diagnosed with skin diseases involving the whole body such as atopic dermatitis (AD). (2) Patients with serious heart, brain, liver, kidney, blood and other systemic diseases, autoimmune diseases, chronic serious infections, and other serious diseases that may affect the evaluation of skin barrier function. (3) The discontinuation time of local glucocorticoids was < 2 weeks, and the discontinuation time of systemic glucocorticoids and other immunosuppressants (tripterygium wilfordis, etc.) was < 4 weeks. (4) Other reasons considered by the researchers not suitable for inclusion. Autistic children: (1) Diagnosis of other mental disorders. (2) Diagnosis of organic brain injury, epilepsy and other neurological diseases. (3) Patients with skin lesions on both forearms, diagnosed with atopic dermatitis (AD), and allergic to cosmetic ingredients. (4) Patients with serious heart, brain, liver, kidney, blood and other systemic diseases, autoimmune diseases, chronic serious infections, and other serious diseases that may affect skin barrier function and ASD related scale assessment. (5) The discontinuation time of local glucocorticoids was < 2 weeks, and the discontinuation time of systemic glucocorticoids and other immunosuppressants (tripterygium wilfordis, etc.) was < 4 weeks. (6) Other reasons considered by the researchers not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transepidermal water loss, TEWL;Stratum corneum hydration, SCH;Skin surface pH;Childhood Autism Rating Scale (CARS) Score;Autism Treatment Evaluation Checklist (ATEC) Score;Autism Behavior Checklist (ABC) Score;Social Responsiveness Scale (SRS) Score;Repetitive Behavior Scale-Revised (RBS-R) Score; | — |
Countries
China
Contacts
Public ContactZhang Guoqiang
The First Hospital of Hebei Medical University
Outcome results
None listed